Company news

Editas Medicine, Inc. news in 2025

Editas Medicine, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies

November 20, 2025

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

November 9, 2025

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

November 2, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

October 8, 2025

Scientific Equipment Goes to Auction in Tiger Group and EquipNet Sale on Oct. 16

October 8, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

October 5, 2025

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

September 1, 2025

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

August 27, 2025

Editas Medicine to Participate in Upcoming Investor Conferences

August 26, 2025

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

August 11, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

June 11, 2025

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 13, 2025

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 11, 2025

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 11, 2025

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

May 4, 2025

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

April 27, 2025

Editas Medicine Announces Chief Financial Officer Transition

March 19, 2025

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

March 4, 2025

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

February 23, 2025

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

January 12, 2025

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Decks in 2025